Exscientia Plc American Depositary Shares

The AI in pharma and biotech market is projected to grow at an 18.8% CAGR, reaching $13.1 billion by 2034. AI is transforming drug discovery and development, accelerating the process and improving patient outcomes.

Related tickers: EXAI.

Recursion Pharmaceuticals and Exscientia announced plans to merge, forming the world's largest biotech focused on AI-powered drug development. The combined company will have a deep pipeline, strong collaborations, and ample cash, making the bull thesis more compelling despite the risks involved.

Related tickers: RXRX, EXAI.